How big is the Restless Legs Syndrome Market?

The Restless Legs Syndrome Market size is expected to reach USD 691.55 million in 2024 and grow at a CAGR of 5.21% to reach USD 891.44 million by 2029. Read More

What is the current Restless Legs Syndrome Market size?

In 2024, the Restless Legs Syndrome Market size is expected to reach USD 691.55 million. Read More

Who are the key players in Restless Legs Syndrome Market?

UCB S.A, Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim International GmbH, Relegs and Azurity Pharmaceuticals, LLC are the major companies operating in the Restless Legs Syndrome Market. Read More

Which is the fastest growing region in Restless Legs Syndrome Market?

Europe is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Restless Legs Syndrome Market?

In 2024, the North America accounts for the largest market share in Restless Legs Syndrome Market. Read More

What years does this Restless Legs Syndrome Market cover, and what was the market size in 2023?

In 2023, the Restless Legs Syndrome Market size was estimated at USD 655.52 million. The report covers the Restless Legs Syndrome Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Restless Legs Syndrome Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Restless Legs Syndrome Market Share

Statistics for the 2023 & 2024 Restless Legs Syndrome market share, created by Mordor Intelligence™ Industry Reports. Restless Legs Syndrome share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Restless Legs Syndrome Industry

The restless legs syndrome market is moderately fragmented in nature due to the presence of several companies operating globally and regionally. The competitive landscape includes analyzing companies Azurity Pharmaceuticals, LLC, Glenmark Pharmaceutical, UCB S.A., Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim International GmbH, Relegs, Restiffic, Viatris Inc., Psychocare Health Private Limited, and Noctrix Health, Inc. among others.